CD20-CD19 Bispecific CAR T Cells for the Treatment of B-Cell Malignancies.
Sign Up to like & getrecommendations! Published in 2017 at "Human gene therapy"
DOI: 10.1089/hum.2017.126
Abstract: The treatment of leukemia/lymphoma by chimeric antigen receptor (CAR) redirected T cells with specificity for CD19 induced complete remissions in the majority of patients, with a realistic hope for cure. However, recent follow-up data revealed… read more here.
Keywords: bispecific car; cd19; cd20 cd19; car cells ... See more keywords
Sustained drug-free remission in rheumatoid arthritis associated with diffuse large B-cell lymphoma following tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy using zamtocabtagene autoleucel
Sign Up to like & getrecommendations! Published in 2024 at "RMD Open"
DOI: 10.1136/rmdopen-2024-004727
Abstract: We report the case of long-term persisting rheumatoid arthritis (RA), treated with CD20-CD19 CAR-T when it became associated with diffuse large B cell lymphoma (DLBCL), resulting in a sustained drug-free remission of the preceding RA,… read more here.
Keywords: therapy; car; cell; rheumatoid arthritis ... See more keywords
Development of NTX-472, a formulated mRNA therapy targeting CD20, CD19, and CD47, for treatment of B-cell lymphoma.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.2537
Abstract: 2537 Background: The approval of anti-CD20 monoclonal antibody Rituximab more than 20 years ago opened a new class of highly effective immunotherapies for the treatment of B cell lymphomas. However, use of treatments that target… read more here.
Keywords: formulated mrna; ntx 472; cell; tumor ... See more keywords